Cullinan Oncology LLC

NASDAQ CGEM

Data sourced from

and

Download Data

Cullinan Oncology LLC Working Capital to Current Liabilities Ratio 2 year CAGR for the year ending December 31, 2023: -18.60%

Cullinan Oncology LLC Working Capital to Current Liabilities Ratio 2 year CAGR is -18.60% for the year ending December 31, 2023, a -190.51% change year over year. The working capital to current liabilities ratio measures the proportion of working capital to current liabilities. It is calculated by dividing the difference between current assets and current liabilities by current liabilities. This ratio indicates the company's ability to cover its current liabilities with its working capital. A higher ratio suggests a healthier liquidity position and better ability to meet short-term obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Cullinan Oncology LLC Working Capital to Current Liabilities Ratio for the year ending December 31, 2022 was 20.09, a -17.15% change year over year.
Cullinan Oncology LLC Working Capital to Current Liabilities Ratio for the year ending December 31, 2021 was 24.25, a 75.41% change year over year.
Cullinan Oncology LLC Working Capital to Current Liabilities Ratio for the year ending December 31, 2020 was 13.82, a -64.25% change year over year.
Cullinan Oncology LLC Working Capital to Current Liabilities Ratio for the year ending December 31, 2019 was 38.67, a 55.65% change year over year.

NASDAQ: CGEM

Cullinan Oncology LLC

CEO	Mr. Nadim Ahmed
IPO Date	Jan. 8, 2021
Location	United States
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Employees	85
Sector	Healthcare
Industry	Biotechnology

Description

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Key trends